A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

被引：0
|
作者：
Justin M Balko
Esther P Black
机构：
[1] College of Pharmacy,Department of Pharmaceutical Sciences
[2] University of Kentucky,undefined
来源：
BMC Cancer | / 9卷
关键词：
Progression Free Survival; Cetuximab; Erlotinib; KRAS Mutation; Lung Cancer Cell Line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Federico, Federica
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    Amico, Maria D'
    Chetri, Maria Concetta
    Cinefra, Margherita
    Ferrara, Pasqualinda
    Cinieri, Saverio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
    Laurent-Puig, Pierre
    Cayre, Anne
    Manceau, Gilles
    Buc, Emmanuel
    Bachet, Jean-Baptiste
    Lecomte, Thierry
    Rougier, Philippe
    Lievre, Astrid
    Landi, Bruno
    Boige, Valerie
    Ducreux, Michel
    Ychou, Marc
    Bibeau, Frederic
    Bouche, Olivier
    Reid, Julia
    Stone, Steven
    Penault-Llorca, Frederique
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5924 - 5930
  • [33] Cetuximab significantly improves progression-free survival and disease control in metastatic colorectal cancer patients
    不详
    ONCOLOGY-NEW YORK, 2007, 21 (06): : 739 - 739
  • [34] Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
    Chen, Yu
    Shi, Yi
    Lin, Jing
    Ye, Yun-bin
    Wang, Xiao-jie
    Chen, Gang
    Guo, Zeng-qing
    MEDICINE, 2015, 94 (40)
  • [35] Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients
    Jing Gao
    Chinese Journal of Cancer Research, 2011, 23 (04) : 271 - 275
  • [36] Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
    Gao, Jing
    Wang, Ting-ting
    Yu, Jing-wei
    Li, Yan-yan
    Shen, Lin
    CHINESE JOURNAL OF CANCER RESEARCH, 2011, 23 (04) : 271 - 275
  • [37] DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease
    De Roock, W.
    Janssens, M.
    Biesmans, B.
    Jacobs, B.
    De Schutter, J.
    Humblet, Y.
    Peeters, M.
    Van Cutsem, E.
    Marynen, P.
    Tejpar, S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 33 - 33
  • [38] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [39] Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer
    Boige, Valerie
    Blons, Helene
    Francois, Eric
    Ben Abdelghani, Meher
    Phelip, Jean-Marc
    Le Brun-Ly, Valerie
    Mineur, Laurent
    Galais, Marie Pierre
    Villing, Anne-Laure
    Hautefeuille, Vincent
    Miglianico, Laurent
    De La Fouchardiere, Christelle
    Genet, Dominique
    Levasseur, Nadia
    Levache, Charles-Briac
    Penel, Nicolas
    Mitry, Emmanuel
    Jacquot, Stephane
    Aparicio, Thomas
    Brument, Emilie
    Gourgou, Sophie
    Castan, Florence
    Bouche, Olivier
    JAMA NETWORK OPEN, 2023, 6 (09) : e2333533
  • [40] Longer progression-free survival with targeted therapy for patients with metastatic breast cancer
    Nierengarten, Mary Beth
    CANCER, 2025, 131 (07)
12345